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Natural antibodies to gp41 inhibit HIV-1 replication through the recognition of two different regions,
corresponding to the leucine zipper motif in the HR1 alpha-helix and to another motif within HR2
region, hosting 2F5 and 4E10 epitope. This study aimed at reproducing such protective responses
through VLP vaccination. Six regions covering the alpha-helical regions of gp41 were conjugated to the
surface of AP205 phage-based VLPs. Once administered in mice via systemic or mucosal route, these
immunogens elicited high titers of gp41-speciﬁc IgG. Immunogenicity and HIV infectivity reduction
were obtained either with HR2 regions or with peptides where aminoacid strings were added to either
the C-terminus or N-terminus of core epitope in HR1 region. Antibody-dependent cell cytotoxicity
(ADCC) activity was induced by one of the HR2 epitopes only. These results may have relevant
implications for the development of new vaccinal approaches against HIV infection.
& 2012 Elsevier Inc. All rights reserved.Introduction
HIV-infected individuals may rarely develop high titers of
neutralizing antibodies (NAbs), but only few regions of Env
proteins have been associated to neutralization (Ferrantelli
et al., 2004; Gray et al., 2007; Guevara et al., 2002; Kirchherr
et al., 2011; Lallemant et al., 1994; Lynch et al., 2011; Moore et al.,
2009a; Moore et al., 2009b; Rong et al., 2007, 2009; Ruprecht
et al., 2001), thus the induction of broadly cross-neutralizing
antibodies remains one of the major goal to generate an effective
protective vaccine. Few monoclonal antibodies (mAbs) recogniz-
ing the membrane-proximal external region (MPER) of gp41, such
as 2F5, 4E10 and Z13, display neutralizing properties; a similar
antiviral activity targets another epitope within the N-terminal
alpha-helical region (HR1), associated to HIV resistance in
exposed but uninfected subjects (Clerici et al., 2002; Jain and
Rosenthal, 2011; Kaul et al., 2001; Tudor et al., 2009; Zwick et al.,
2001). However, gp41 is a key target in various humoral-
mediated mechanisms, such as antibody-dependent cell cytotoxi-
city (ADCC) and inhibition of transcytosis across epithelial cellll rights reserved.
iomedical Research, Basel,layers, that were recently found protective in mucosal districts
even in the absence of circulating neutralizing antibodies (Bomsel
et al., 2011).
The most promising scenarios in HIV vaccinology deal with the
generation of novel immunogenic systems, capable of preserving
native alpha-helical conformation and/or the trimeric structure of
immunodominant neutralizable epitopes. In this study, we com-
pared humoral responses to various gp41 epitopes, which were
covalently conjugated via a chemical crosslinker to virus-like
particles (VLPs) derived from bacteriophage AP205.
Bacteriophage VLPs offer a modular vaccine approach, which
allows separate synthesis of the native VLP and the target
antigens. AP205 VLPs can be produced in large-scale by recombi-
nant expression of the AP205 coat protein in E. coli and by
subsequent self-assembly of the monomers into native VLPs. Each
VLP consists in 180 monomers, resembling native virus capsids.
Several peptide strings can be conjugated to a single AP205
subunit, achieving a very high peptide density on the VLP surface.
The generation of repetitive and ordered peptide lattice on VLPs,
either derived from bacteriophage AP205 (Spohn et al., 2010) or
bacteriophage Qb (Jennings and Bachmann, 2008), strongly acti-
vates B cells and rapid and robust speciﬁc antibody responses can
be achieved (Hinton et al., 2008). These features of gp41-VLPs,
similar to virus properties, lead to direct activation of gp41-
speciﬁc B-cells and of the complement cascade; binding of natural
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cells. Moreover, the particulate nature of VLPs vaccines enhances
uptake by dendritic cells by its own and stimulates antigen
presentation in association with either MHC class II and class I
molecules (Jennings and Bachmann, 2008). Finally, single-
stranded RNA (ssRNA), derived from the E. coli host, packaged
within VLP particles during their self-assembly, works as an
immune adjuvant through Toll-like receptors, therefore it further
reinforces APC recruitment and, consequently B-cell activation
and B-cell class switch recombination (Gamvrellis et al., 2004;
Jegerlehner et al., 2007).Fig. 1. VLP-Antigen coupling and density. Panel A: gp41 peptides were coupled to
AP205 VLPs through a bifunctional cross-linker, succinimidyl-6-(b-maleimidopro-
pionamido)-hexanoate (SMPH), that associated lysine residues in AP205 monomer
proteins and the six antigens to be exposed on particles. Panel B: antigen (Ag)
density on VLP surface, as determined by SDS-PAGE analysis and band densito-
metry; the proportion of mono-, bi- or triple-antigen density on single surface
monomers is reported.Results
Production of the AP205 VLP carrier
The ssRNA bacteriophage AP205 is a positive strand-RNA coliph-
age belonging to the family of Leviviridae, which can infect a wide
variety of Gram-negative bacteria and has been ﬁrst isolated from
Acinetobacter species (Klovins et al., 2002). In analogy to related
phages Qb (Cielens et al., 2000; van denWorm et al., 2006) and MS2
(Peabody, 1990), recombinant AP205 coat protein expressed in
E. coli undergoes self-assembly into virus-like particles (VLPs)
(Tissot et al., 2010). Recombinant auto-assembled AP205 VLPs are
similar in shape and size to MS2 and to AP205 wild-type particles
(T¼3 icosahedral particles of 29 nm observed by electron micro-
scopy) and contain 25–30 mg host cell RNA per 100 mg of coat
protein, as determined by spectrophotometric analysis (Koning
et al., 2003; Spohn et al., 2010; van den Worm et al., 2006).
Assembly and quality control of AP205-gp41 peptide conjugates
We have previously shown that antigens which are conjugated
in a highly repetitive and ordered fashion to the surface of VLPs
derived from bacteriophage Qb (Jennings and Bachmann, 2008),
another icosahedral T¼3 phage particle, or AP205 (Spohn et al.,
2010) can induce rapid and robust antibody responses due to
strong cross-linking of speciﬁc B-cell receptors. A hetero-bifunc-
tional crosslinker was used to covalently conjugate the gp41
peptides 3-13, 3-17, 3-20, 3-24, P1 and P8 via the introduced
C-terminal cysteine residue to lysine residues on the surface of
AP205 VLPs (Fig. 1). All six peptides were efﬁciently conjugated to
AP205 VLPs reaching very high peptide densities on the AP205
VLPs, as shown in Fig. 2, panels A–C.
Due to the key importance of peptide crowding on VLPs
surface, conjugate vaccines were analyzed by SDS-PAGE to deter-
mine the number of peptides cross-linked to a single AP205 VLP.
As shown in Fig. 2, molecular weights of bands run in a reducing,
denaturing SDS-PAGE gel corresponded to AP205 subunit asso-
ciated with one, two or three peptides.
AP205 VLPs consist of 180 coat proteins (subunits) and each of
the subunits can be conjugated to several peptides. If the VLPs are
loaded on a reducing SDS-PAGE Gel the individual subunits can be
seen as distinct bands. One VLP consists of subunits, which are
conjugated to three, two, one or zero peptides and the average
number of peptides per VLP are indicated (Fig. 1). According to
AF4 analysis which has been performed with similar preparations
only one peak per preparation could be seen and the peak was
shifted compared to non-conjugated AP205 which indicated that
all AP205 VLPs in a preparation where conjugated to a similar
amount of peptides following a normal distribution, so there was
no need for puriﬁcation prior to immunization. Due to different
length and hydrophobicity of the peptides the number of pep-
tides, which can be conjugated to VLPs, is variable and part of this
feasibility study was to evaluate the possibility to conjugate thesepeptides to VLPs. For each peptide optimal conditions for con-
jugation have been developed.
Densitometric analysis of the corresponding bands allowed us
to estimate the mean number of peptides conjugated to a single
AP205 VLP; we calculated 370 peptides for AP205-3-13, 270
peptides for AP205-3-17, 390 peptides for AP205-gp41-3-20 and
240 peptides for AP205-3-24, 40 peptides for AP205-P1 and 70
peptides for AP205-P8 conjugate vaccines, respectively. We next
evaluated whether neutralizing epitopes on P1 and P8 were still
accessible at the surface of AP205-P1 and AP205-P8 VLPs after
coupling, by mean of a sandwich ELISA method. This was not
necessary for the other gp41-AP205 VLPs, due to the shorter
length of their peptides (13–24 aa vs. 40–66 aa) and the
consequent limitation in their possible conformations.
VLPs were bound to the solid support using an AP205 anti-
serum; the two broadly neutralizing IgG 2F5 and 4E10 were
added to reveal bound VLPs, AP205-P1 or AP205-P8, and detected
with a secondary anti-human antibody coupled to HRP. Fig. 2,
panel D shows that both broadly neutralizing 2F5 and 4E10
recognized AP205-P1 or AP205-P8 at sub-nanomolar range,
although AP205-P8 exhibited a better accessibility than AP205-
P1 to both IgGs; in other words, P1 and P8 were readily accessible
at the VLP surface and retained a full exposure of their neutraliz-
ing determinants.
Immunogenicity of gp41 peptides in mice
Groups of ﬁve mice were immunized subcutaneously with
AP205 conjugate vaccines including AP205-3-13, AP205-3-17,
AP205-3-20, AP205-3-24. Peptide-speciﬁc antibody titers were
determined after three and ﬁve immunizations and compared
with pre-immune titers (Fig. 3, panel A). High-titer, speciﬁc
antibodies were obtained after three immunizations with all four
conjugate vaccines; titers further increased after ﬁve immuniza-
tions. AP205-3-20 conjugate vaccine achieved the highest anti-
body titers.
Fig. 2. Production and characterization of the AP205-gp41-peptides conjugate vaccines. Panel A: Corresponding amounts of derivatized AP205 (AP205) and AP205-gp41.3-
20 (AP205-3-20), AP205-gp41-3-13 (AP205-3-13), AP205-gp41-3-24 (AP205-3-24), AP205-gp41-3-17 (AP205-3-17) conjugate vaccines were analyzed by reducing,
denaturing SDS-PAGE. The lowest band ‘‘AP205’’ represents the AP205-subunit alone, bands ‘‘AP205-Antigen1’’, ‘‘AP205-Antigen2’’ and ‘‘AP205-Antigen3’’ represents an
AP205-subunit conjugated to 1, 2 or 3 peptides, respectively. The relative intensity of the bands marked with arrows was quantiﬁed by densitometry and the amount of
peptides per AP205 VLP was calculated. Panels B and C: Corresponding amounts of derivatized AP205 (AP205) and AP205-gp41-P1 (AP205-P1) (panel B), AP205-gp41-P8
(panel C) conjugate vaccines were analyzed by reducing, denaturing SDS-PAGE. The lowest band ‘‘AP205’’ represents the AP205-subunit alone, bands ‘‘AP205-Antigen1’’,
‘‘AP205-Antigen2’’ and ‘‘AP2052-Antigen’’ and ‘‘AP2052-Antigen2’’ represents one AP205-subunit or one AP205-subunit-Dimer conjugated to 1 or 2 peptides. The relative
intensity of the bands marked with arrows was quantiﬁed by densitometry and the amount of peptides per AP205 VLP was calculated. Panel D: 2F5 and 4E10 binding to
AP205-P1 and -P8 VLPs. 2F5 and 4E10 mAbs were used at different concentrations (nM).
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neously or intranasally with AP205-P1 and AP205-P8 conjugate
vaccines. Peptide-speciﬁc antibody titers were determined
either after three and four immunizations for P1 or after two
and three immunizations for P8 and compared with pre-
immune titers: high titers were reached after two, three or
four immunizations, respectively (Fig. 3, panel B). Intranasal
immunizations elicited lower titers in comparison with those
elicited by subcutaneous route.Speciﬁcity of antisera to P1 and P8 peptides
We next evaluated whether sera from mice immunized with
AP205-P1 and AP205-P8 recognized epitopes similar to these
bound by the broadly neutralizing 2F5 and 4E10 mAbs. Therefore,
increasing concentrations of immune sera bound to immobilized
P1 or P8 were allowed to compete with an excess of 2F5 or 4E10
mAbs, respectively. In contrast to 2F5 IgG, 4E10 competed with
AP205-P1 sera obtained from both intranasal and subcutaneous
Fig. 3. Immunogenicity of AP205-gp41-peptides conjugate vaccines. Panel A: Immunizations with HR1 peptides. Groups of female Balb/c mice (n¼5) were immunized
subcutaneously three times with 50 mg and two times with 100 mg AP205-3-13, AP205-3-17, AP205-3-20, AP205-3-24 and AP205 conjugate vaccines, in the absence of
adjuvants. Sera to AP205 were tested against 3-24 peptide. Panel B: Immunizations with HR2 regions. Groups of female Balb/c mice (n¼5) were immunized
subcutaneously four times with 50 mg of AP205-P1 and AP205-P8 conjugate vaccine, in the absence of adjuvants. Sera to AP205 against P8 peptide were also shown.
Antibody titers are shown as the reciprocals of the dilution needed to achieve 50% of the signal measured at saturation (OD50 titers). Panels C and D: 2F5 and 4E10
competition ELISA with antisera to AP205-P1 and AP205-P8 vaccines on immobilized P1 and P8 antigens, respectively. O.D. values at 450 nm are shown.
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even higher (around 85%) with AP205-P8 sera, whereas competi-
tion by 2F5 was around 50% (Fig. 3, panel D). The speciﬁcity of
competition was obtained by preincubation of 2F5 or 4E10 to
AP205 carrier protein and no competition was shown (Fig. 3,
panels C and D). These results indicated that AP205-P1 and
AP205-P8 immunizations effectively induced 4E10-like IgG in
mice sera, but only AP205-P8 could induce 2F5-like antibodies.
AP205 gp41 VLPs induce neutralizing antibodies
The pool of immune sera taken after the last immunization to
each antigen was assayed in neutralization assays on four HIV-1
strains: the high-sensitive, laboratory strain SF162 (R5-B), the
low-sensitive, primary isolates AC10 and QH0692 (both R5-B) and
a clade C primary isolate, ZM214. Table 1 shows the sequences
similarities among gp41 peptides and viruses used in neutraliza-
tion assays.
Data, summarized in Fig. 4, showed that antisera to all gp41-
VLPs except AP205-3-24 reduced HIV infectivity of SF162 (mean
IC50 1:501:100), two of these also neutralized AC10 (mean IC50
1:401:80). ZM214 isolate was not neutralized by all serum
samples, but the other clade B train, QH692, was neutralized byAP205-3-20 only (mean IC50 1:50). As a whole, anti-sera to
AP205-3-20 showed the best neutralizing activity, with a mean
IC50 of 1:78.
Anti-sera to AP205-P1 showed very low neutralizing activ-
ity, while AP205-P8 induced neutralizing antibodies with a
mean IC50 of 1:73.5 for sera from mice immunized subcuta-
neously and 1:33 for mice immunized by intranasal route. Of
note is that anti-sera to P8 efﬁciently neutralized one clade C
virus (ZM214), thus representing an interesting tool for further
investigation in cross clade neutralization. As positive control
TRIMAB was used against all viruses and showed a mean IC50
ranging 0.45–17.12 mg/ml and IC90 ranging 0.76–27.73 mg/ml as
shown in Fig. 4C. The absence of neutralizing activity either by
preimmune or by AP205 sera (Fig. 4A) and the fact that not all
viruses have been neutralized demonstrates the absence of
toxicity in cell cultures.
To verify that the neutralization was contained in immuno-
globulin fractions rather than to other soluble factors, puriﬁed Igs
from the pool of sera from the last immunization to AP205-3-17,
AP205-3-20, AP205-P8 s.c. and AP205-P8 i.n. were tested against
all viruses and showed a mean IC50 ranging from a corresponding
serum dilution 1/10 to 1/150, thus conﬁrming that neutralization
was due to Igs fraction as shown in Fig. 4B.
Table 1
Peptides sequence and similarities with viral strains used in neutralization assays.
Region Sequence
AP205-3-13 LQARILAVERYL
SF162 LQARVLAVERYL
ZM214 LQARVLAIERYL
QH0692 LQARVLAVERYL
AC10 LQARVLAVERYL
AP205-3-17 GIKQLQARILAVERYL
SF162 GIKQLQARVLAVERYL
ZM214 GIKQLQARVLAIERYL
QH0692 GIKQLQARVLAVERYL
AC10 GIKQLQARVLAVERYL
AP205-3-20 LQARILAVERYLKDQQLLG
SF162 LQARVLAVERYLKDQQLLG
ZM214 LQARVLAIERYLKDQQLLG
QH0692 LQARVLAVERYLRDQQLLG
AC10 LQARVLAVERYLRDQQLLG
AP205-3-24 GIKQLQARILAVERYLKDQQLLG
SF162 GIKQLQARVLAVERYLKDQQLLG
ZM214 GIKQLQARVLAIERYLKDQQLLG
QH0692 GIKQLQARVLAVERYLRDQQLLG
AC10 GIKQLQARVLAVERYLRDQQLLG
AP205-P1 SLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIK
SF162 TLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYIK
ZM214 RLLEVSQNQQEKNEEDLLALDKWDNLWNWFDISKWLWYIK
QH0692 SLLEDSQNQQEKNEHELLELDKWASLWNWFDITRWLWYK
AC10 TLIEESQNQQEKNEQELLALDKWANLWNWFNITEWLWYIK
AP20-P8 SLEQIWNTHTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIK
SF162 SLDQIWNNMTWMEWEREIDNYTNLIYTLIEESQNQQEKNEQELLELDKWASLWNWFDISKWLWYIK
ZM214 SVDDIWQNMTWMQWDREINNYTEIIYRLLEVSQNQQEKNEEDLLALDKWDNLWNWFDISKWLWYIK
QH0692 SQDYIWNNMTWMQWDKEINNYTNLIYSLLEDSQNQQEKNEHELLELDKWASLWNWFDITRWLWYIK
AC10 SVDDIWENMTWMQWDREISNYTSLIYTLIEESQNQQEKNEQELLALDKWANLWNWFNITEWLWYIK
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In addition to neutralizing activity, IgG antibodies can also
exert another antiviral activity using both their variable and
constant domains, i.e. the induction of cytotoxic killing of a cell
infected with HIV-1 by an effector cell expressing an Fc-gamma
receptor. We evaluated ADCC of all immune sera from all
vaccinated mice group using a previously described assay
(Tudor and Bomsel, 2011).
Whereas no ADCC activity could be detected in all antisera
(not shown), AP205-P1 vaccination by intranasal route induced a
low, although signiﬁcant, ADCC activity (Fig. 5, panel A), and a
higher activity in AP205-P8 sera, especially in samples from the
intranasal vaccinees than in those from the subcutaneous ones
(Fig. 5, panel B).
In order to conﬁrm that ADCC was indeed due to serum IgG
and not to other serum factors, effector cells where pre-incubated
with pre-immune mouse IgG to compete with gp41-speciﬁc
serum IgG from vaccinated mice. As expected, pre-incubation
with IgG completely abrogated AP205-P1 and -P8 induced ADCC
(Fig. 5, panel C).
ADCC epitopes are most likely situated in the 625-250 region
of gp41, or could be conformational epitopes that can only be
reconstituted in large peptides, such as the P8 peptide. Therefore
we assessed whether the high ADCC activity shown by AP205-P8
sera was due to the additional region present in P8 peptide that
was not covered by P1. At this purpose, ADCC activity of AP205-P8
sera was evaluated using P1 and P8-coated target cells, respec-
tively. In these conditions, ADCC activity of AP205-P8 intranasal
sera was restricted to the P8 peptide, since P1-coated target cells
were not lysed by effector cells (Fig. 5, panel D). Negative control
sera, obtained from placebo-vaccinated mice, could not induce
ADCC either of P1 or of P8 coated cells (Fig. 5, panel D). This set ofassays shows that only vaccination with AP205-P8 by the intra-
nasal route induced speciﬁc IgG, endowed with a robust ADCC
activity.Conclusion
Bacteriophage virus-like particles (AP205) are a type of recom-
binant subunit vaccines that offer many advantages in terms of
versatility and safety. Their core is made of viral structural
proteins able to self-assemble into capsid-like structures, simi-
larly to natural virus. VLPs maintain conformation and size
similar to their pathogenic counterparts, but are not harmful to
hosts, since they lack infectious nucleic acids and replication
machinery (Kratz et al., 1999; Tissot et al., 2010). Recombinant
bacteriophage AP205 produced in E. coli bacteria are highly
immunogenic but cannot replicate in non-natural, non-permis-
sive hosts such as the Vertebrates (Rohn et al., 2011). Due to their
size and their structure, AP205 are efﬁciently captured and
presented by antigen presenting cells, and therefore elicit a strong
adaptive immune response that is even able to overcome immune
tolerance to self-antigens, as shown by results of recent preclini-
cal and clinical studies (Rohn et al., 2011; Spohn et al., 2005;
Tissot et al., 2008). AP205 surface can display organized and
dense antigens arrays, able to cross-link B cell receptors and to
induce a strong humoral response (Bachmann and Zinkernagel,
1997; Fehr et al., 1997).
AP205 is a recently isolated phage, suitable to provide versatile
VLPs that can elicit prompt and strong immune responses in
Mammalians (Spohn et al., 2010; Tissot et al., 2010). One of the
key features of AP205 is the high density of vaccinal antigens that
each particle can host: the higher antigen density, the higher B
cell activation will be achieved. In this study, AP205-VLP were
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Fig. 4. Infectivity reduction by antisera to AP205-gp41 peptide conjugate vaccines. Neutralization activity was evaluated through 4 different viruses, including SF162,
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samples were tested in duplicate and the mean values and errors bars were shown.
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erated strong speciﬁc humoral responses upon vaccination even
in the absence of adjuvant molecules.
In detail, higher peptide density was achieved when AP205-
associated peptides were added with long C-terminal tails: as
shown in Table 1, AP205-3-13 and AP205-3-20 achieved higher
peptide density than AP205-3-17 and AP205-3-24, which hosted
peptides associated with N-terminal tails.
In such AP205, the highest peptide monomer densities were
observed, i.e. two peptide/monomer, with a variable proportion of
three peptide/monomer (7% in AP205-3-13 and 16% in AP205-3-20, respectively); conversely, AP205-3-17 and AP205-3-24 did not
obtain an uniform double peptide binding on their surface (51%
and 34%, respectively; Fig. 1).
Due to their dimension, HR2-speciﬁc peptides, i.e. P1 and P8,
also showed lower array density (single peptide/monomer arrays
in 22.78% and 37.22%, respectively), however by far higher that
the density of Env spikes observed on the surface of native HIV
virions (Zhu et al., 2006). Due to the relatively large surface
disposition allowed these P1 and P8 peptides to achieve a proper
three-dimensional conformation. As a further conﬁrm of AP205
suitability, both HR1- and HR2-speciﬁc peptides on AP205 surface
Fig. 5. ADCC activity. ADCC activity was evaluated as described (Tudor and Bomsel, 2011) using THP1 expressing Fc-gammaRI as effector cells and NKr-CEM coated with
either P1 or P8 peptide, as indicated. ADCC is evaluated in % of speciﬁc lysis corresponding to speciﬁc target cell lysis minus lysis in the presence of non-speciﬁc mouse
serum as the same dilution. Panel A: Sera from AP205-P1 vaccinated mice (dilution 1:100 and1:200) immunized by the i.n. route exhibit a signiﬁcant, although low, ADCC
of P1-coated target cells. Positive control was the 2F5 IgG at the indicated concentration. In contrast, the s.c. route of immunization was unable to induce ADCC in sera.
Panel B: Serum from AP205-P8 vaccinated mice (dilution 1:100 and 1:200) immunized by the i.n. and the s.c. route exhibited a robust ADCC of P8 coated target cells.
Positive control was the 2F5 IgG at the indicated concentration. Panel C: Sera from AP205-P8 vaccinated mice (dilution 1:100 and 1:200) immunized by the i.n. and the s.c.
route showed a robust ADCC activity on P8 coated target cells; ADCC was abrogated by pre-incubation of effector cells with an excess of normal mouse IgG. Positive control
was the 2F5 IgG at the indicated concentration. Panel D: Sera from AP205-P8 vaccinated mice (dilution 1:200) immunized by the i.n. route induced a robust ADCC of
P8-coated, but not P1-coated, target cells. AP205-placebo sera lacked ADCC activity. Positive control was the 2F5 IgG at the indicated concentration.
C. Pastori et al. / Virology 431 (2012) 1–11 7were found to be well exposed, properly folded and accessible to
speciﬁc antibodies, as shown by their strong immunogenicity
upon s.c. or i.n. administration. AP205-P1 and AP205-P8 were also
found reactive with MPER-speciﬁc mAbs, therefore showing that
exposed peptides displayed a proper folding and are readily
accessible to antibodies (AP205-P1-8: Fig. 2D).
When AP205 were administered as immunogen, high antibody
titers were already observed at after three doses, further rein-
forced after the ﬁfth administration. Among HR1-speciﬁc immu-
nogens, AP205-3-20 showed the highest titers, suggesting that its
C-terminal tail favored a suitable conformation and exposure and
enhanced VLP immunogenicity in respect to other peptide
arrangements (Fig. 3A). Moreover, the dense peptide array dis-
played on these AP205 should have promoted an intense APC
stimulation and/or speciﬁc B cell responses. This hypothesis is
further reinforced by the neutralization efﬁcacy shown by AP205-3-20 anti-sera, that showed highest titers among HR1 antigens
and was able to neutralize three out of the four virus strains
tested in the assay (Fig. 4A). Surprisingly, AP205-3-17 anti-sera
displayed neutralizing antibodies against two virus strains, while
AP205-3-13 anti-sera only neutralized the SF162 laboratory
strain; this effect could be explained by a more effective con-
formation of peptide 3-17, due to its superior length or to its
lower density on the AP205 surface, that could have given room
to a more relaxed three-dimensional folding.
As shown by previous studies (Bomsel et al., 2011), AP205-P8
anti-sera reached higher titer values at the ﬁfth immunization
than -P1 ones (Fig. 3B); the former AP205 also induced anti-2F5
antibodies, able to compete with the homologous mAb, while
AP205-P1 anti-sera only displayed anti-4E10 antibodies active in
competition assays (Fig. 3C and D). The higher efﬁcacy of P8, also
evident in neutralization assays (Fig. 4A), could be due to its
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the native MPER conformation, able to display one or more key
epitopes for HIV neutralization.
Native MPER domain is closely associated with membrane
lipids and it is generally buried within env spikes; upon CD4
binding, env conformation opens and MPER becomes transi-
ently exposed just before virus entry, allowing antibody bind-
ing and virus neutralization for a short time window.
Laboratory HIV strains show a more relaxed conformation, that
makes antibody access easier, while primary isolates and
resistant strains display a tight, poor accessible env conforma-
tion, also sustained by env mutations spread in the whole
protein sequence and by glycosylation shield (Chakrabarti
et al., 2011; Ma et al., 2011). Due to these features, antibodies
to MPER were not frequently observed in the course of natural
infection but, when present, they were associated with virus
neutralization and protection, as shown in a cohort of South
African mothers and newborns (Diomede et al., 2012).
Peptides and synthetic immunogens can successfully focus
immune response to speciﬁc neutralizing env epitopes and elicit
broad neutralizing antibodies recognizing MPER, because they
can provide selected MPER epitopes in ‘‘frozen’’, antibody-acces-
sible conformations for a longer time, therefore enhancing immu-
nogenicity of speciﬁc MPER epitopes (Bomsel et al., 2011; Jain
et al., 2010; Zhou et al., 2012). Epitope selection, impossible to be
achieved in native antigens, prevents the generation of parasite
responses to immunodominant but unprotective epitopes, such as
immunodominant epitope (C–C loop), while favoring the produc-
tion of broad neutralizing antibodies to MPER, provided that
delivery systems be able to present epitopes shaped in proper
conformations (Alam et al., 2008; Diomede et al., 2012).
As a conﬁrm, such approaches also led to generation of
neutralizing antibodies with rare speciﬁcities, overlapping with
2F5 and 4E10 epitopes, which are seldom observed in natural
infection or in immunization with native antigens (Morris et al.,
2011; Zhou et al., 2012).
Finally, simultaneous presentation of multiple MPER epitopes,
made possible by VLPs and other innovative immunogens,
increases engagement of APC and B cells, giving rise to higher
antibody titers and faster responses upon immunization (Jain
et al., 2010).
These features of novel immunogens overcome limits of natural
immunogens and deeply impact vaccine design, leading the way to
new approaches to HIV vaccinology. Well-designed immunogens,
coupled with speciﬁc prime-boost immunization schedules and
proper adjuvants, can address both innate and adaptive arms of
immunity, giving rise to systemic and/or to mucosal responses that
are the key to confer early HIV protection. Novel immunogens
based on MPER epitopes were also shown to elicit mucosal
responses different from virus neutralization, such as ADCC and
block of virus transcytosis, which can provide key barriers to HIV
entry and protect gut immunity, which is the major immune
reservoir in the host (Bomsel et al., 2011; Jain et al., 2010).
Despite intranasal administration of AP205 induced lower
antibody titers and was associated with reduced neutralization
potential (Fig. 4A), this route of vaccination was more effective in
inducing antibodies able to drive ADCC activity (Fig. 5A–C). P8
antigens were more effective than P1 also in eliciting antibodies
capable of targeting effector cells to speciﬁc killing: this could be
probably related to the induction of 2F5-like antibodies, since 2F5
was found able to drive ADCC activity.
In conclusion, VLPs generated by AP205 carrier protein were
found to host dense arrays of antigens on their surface, properly
folded and therefore highly immunogenic. In detail, AP205-3-20
and AP205-P8 hosted the more crowded arrays of HR1 and MPER-
derived peptides (i.e. 390 and 70 molecules/particle, respectively;Fig. 1). AP205-3-20 did not host the longest HR1 peptide, never-
theless it showed the highest neutralization potential in the study
(Fig. 4). Similar results were also reported by other immunization
studies, where the increasing number of antigenic motifs within
the immunogen was associated with stronger antibody responses
(Fehr et al., 1997; Jain et al., 2010).
Due to the dense surface array as well as to its long and
properly folded aminoacid string, P8 immunogen gave rise to
antibodies mediating ADCC (Fig. 5), which are considered a key
correlate of protection from HIV infection (Bomsel et al., 2011).
Our results support the effectiveness of novel VLP immuno-
gens employing dense antigens arrays and encourage the
further characterization of these VLPs in immunization studies.
In particular, based on our results, AP205 3-17, AP205-3-20 and
AP205-P8 could be selected for further characterization of a
vaccine candidate. Multiple routes of administration, higher
density of such conjugated peptides could be exploited to
increase the immunogenicity, as well as to investigate routes
and schedules suitable to elicit local immunity, e.g. the gen-
eration of mucosal IgA.Materials and methods
Production of AP205 VLP
The cDNA encoding the viral capsid protein of the RNA-phage
AP205 was introduced into the EcoRI/HindIII restriction sites of
expression vector pTacnSD under control of a strong tac promoter
and transformed into the E. coli host strain RB791. Expression of the
capsid protein was induced by addition of 1 mM IPTG for 4 h at 37 1C.
Cells were puriﬁed by centrifugation and resuspended in anion
exchange chromatography loading buffer (20 mM sodium phosphate,
pH 7.2). The mixture was sonicated ﬁve times with 22 kHz for 15 s,
with intervals of 1 min to cool the solution on ice. E. coli lysate
containing the expressed coat protein was cleared by Benzonase
treatment (5 U/mL, Novagen) followed by centrifugation. Viral cap-
sids were puriﬁed by anion exchange chromatography (FractogelTM
TMAE (M), Merck). Bacterial host cell proteins were removed by a salt
wash with 333mM NaCl, and capsids were eluted at 600mM NaCl.
Finally, the puriﬁed capsids were polished by gel ﬁltration chromato-
graphy (CL-4B sepharose, Amersham) using PBS as running buffer and
stored at 80 1C. This puriﬁcation protocol allowed to purify the
AP205 VLPs from bacterial host cell proteins and residual benzonase
protein due to the differences in the isoelectric point of the proteins
and VLPs as well as differences in the molecular weight or proteins
and VLPs. Analysis of the AP205 VLPs by SDS page chromatography
showed that the purity of the AP205 VLPs was over 95%. The amount
of host cell RNA packaged into recombinant AP205 VLP was deter-
mined by spectrophotometric analysis and was 25–30 mg host cell
ssRNA (E. coli mRNA and tRNA) per 100 mg of coat protein.
Chemical coupling of gp41 peptides to AP205 VLP
AP205 VLPs (dissolved in HEPES, pH 7.2) were ﬁrst allowed to
react with a 20-fold molar excess of the heterobifunctional
crosslinker succinimidyl-6-(b-maleimidopropionamido)-hexano-
ate (SMPH) (PIERCE, Rockford, USA) for 1 h at RT. Free, unreacted
crosslinker was removed by dialysis using a Spectra/Pors6 50
MWCO dialysis membrane (SPECTRUMs LABORATORIES INC., CA,
USA) against coupling buffer (20 mM HEPES, pH 7.2) overnight at
4 1C. Derivatized AP205 was mixed with 2-fold or 5-fold molar
excesses of the following peptides to produce conjugate vaccines:
Gp41-03-13 (NH2-LQARILAVERYLC-CONH2, MW 1547Da), Gp41-03-
17 (NH2-GIKQLQARILAVERYLC-CONH2, MW 1973Da), Gp41-03-
20 (NH2-LQARILAVERYLKDQQLLGC-CONH2, MW 2330Da),
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2756Da), Gp41-P1 (NH2-SQTQQEKNEQELLELDKWASLWNWFDI-
TNWLWYIC-CONH2, MW 4460Da) and Gp41-P8 (NH2-SWSNK-
SLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL-
DKWASLWNWFNITNWLWYIKC-CONH2, MW 9074Da). The coupling
reaction was incubated for 4 h at RT. Uncoupled peptide was
removed by dialysis with a Spectra/Pors6 50 MWCO dialysis
membrane (SPECTRUMs LABORATORIES INC., CA, USA). Peptide
density (the number of peptides conjugated to one AP205 VLP)
was determined by SDS-PAGE analysis.
Determination of the number of peptides per AP205 VLP
The molecular weight of one AP205 subunit is 14 kDa; the
molecular weights of the 03-13, 03-17, 03-20, 03-24, P1 and P8
peptides are 1.5 kDa, 1.9 kDa, 2.3 kDa, 2.8 kDa, 4.5 kDa and
9.1 kDa, respectively. A discrete change in molecular weight
representing one peptide coupled to one AP205 subunit can be
visualized as a distinct band in a reducing SDS PAGE Gel. Each
AP205 monomer has several lysine residues and therefore it can
bind more than one peptide via the heterobifunctional crosslinker
SMPH, which is reacting with lysine residues on one side and
cysteine residues on the other side (all gp41 peptides contain a
cysteine residue at their C-terminus). Therefore, each AP205
subunit can be coupled to 1, 2, or 3 peptides, and four distinct
bands on a reducing SDS PAGE Gel would be observed, according
to the number of peptides associated to capsid monomers. To
determine such peptide numbers, we determined the intensity of
SDS-PAGE bands by densitometric analysis and then used the
following formula to determine the number of peptides per each
AP205 VLP, considering it is made of 180 monomers:
Number of peptides=VLP¼ ðbþ2cþ3dÞ=ðaþbþcþdÞ  180,
where a is the intensity of band ‘‘AP205’’, b is the intensity of band
‘‘AP205-peptide’’, c is the intensity of band ‘‘AP205-(peptide)2’’,
and d is the intensity of band ‘‘AP205-(peptide)3’’.
The estimated number of peptides per VLP was the following
for the different conjugate vaccines: AP205-3-13: 370 peptides/
AP205 VLP; AP205-3-17: 270 peptides/AP205 VLP; AP205-3-20:
390 peptides/AP205 VLP; AP205-3-24: 240 peptides/AP205 VLP;
AP205-P1: 40 peptides/AP205 VLP; and AP205-P8: 70 peptides/
AP205 VLP.
The quality of this method to determine the number of peptides
per VLP was veriﬁed by comparing the size of unconjugated AP205
VLPs to the size of AP205 VLPs conjugated to antigens by Asymme-
trical ﬂow ﬁeld-ﬂow fractionation (AF4) (Lang et al., 2009). The
number of antigens per VLP determined by these two different
methods was comparable.
Mice immunizations
Balb/c mice were purchased from Harlan. All animals were
kept under speciﬁc pathogen-free conditions at BioSupport AG
and were used at 8 weeks of age. Experiments were conducted in
accordance with protocols approved by the Swiss Federal Veter-
inary Ofﬁce.
Eight weeks old female Balb/c mice were immunized subcu-
taneously three times with 50 mg and two times with 100 mg of
AP205-gp41 peptide conjugates AP205-3-13, AP205-3-17, AP205-
3-20, AP205-3-24 or with 50 mg of AP205-P1 and -P8 conjugates
every 10 days. AP205-P1 and AP205-P8 vaccines were adminis-
tered intranasally as well. Serum samples were taken 8 days after
last immunization and peptide-speciﬁc antibody titers were
determined before and after immunizations. No adjuvants were
administered.ELISA analysis
ELISA plates (96-well MAXIsorb, NUNC) were coated with
gp41 peptides at a concentration of 10 mg/ml in coating buffer
(0.1 M NaHCO3, pH 9.6). Plates were incubated overnight at 4 1C.
After washing with PBS/0.05% Tween, plates were blocked for 2 h
at 37 1C with 2% BSA/PBS. Then, serum of individual mice was
added in 5-fold serial dilutions (with a starting dilution of 1:200
for the ﬁrst well) and incubated for 2 h at room temperature.
Plates were then washed ﬁve times with PBS/0.05% Tween. Anti-
gp41 antibodies were detected with HRP-labeled goat anti-mouse
IgG antibodies (Jackson Immuno Research Laboratories). The color
reaction was developed with a 0.4 mg/mL solution of 1, 2-ortho-
phenylenediamine dihydrochloride (OPD) in citric acid buffer
(35 mM citric acid, 66 mM Na2HPO4, pH 5.0) containing 0.01%
H2O2. After 7 min the reaction was stopped with a 5% H2SO4
solution in H2O, and plates were read at 450 nm on an ELISA
reader (Biorad Benchmark). Antibody titers are deﬁned as the
reciprocals of the dilution needed to achieve 50% of the signal
measured at saturation (OD50 titers).
Immunoglobulin puriﬁcation
Agarose-coupled with goat anti-mouse Ig antibodies (Sigma-
Aldrich, Milan) was used to purify Ig fractions from pre- and post-
immune sera. Antibodies were obtained by elution with 0.2 M
glycine/HCl buffer (pH 2); eluates were neutralized with 1 M Tris
buffer pH 11. Puriﬁed Ig fractions were concentrated on Ultrafree-
15 Biomax 30 membranes with a cut-off of 30 kDa (Millipore,
Bedford, MA, USA). Microﬁlters was used to concentrate Ig
fractions and to exclude low MW molecules which might inter-
fere with neutralization assays. Eluted Ig from pre- and post-
immune sera and the non-Ig fractions of all sera were dialyzed in
PBS buffer and tested by an ELISA assay on solid-phase anti-
mouse Ig antibodies, in order to determine immunoglobulin
concentration in Ig-enriched fractions and the presence of resi-
dual antibodies in Ig-depleted ones. A commercial mouse Ig
preparation (Sigma Aldrich, Milan, Italy) was used as a standard.
Pseudovirus production for HIV-1 neutralization assay
Neutralizing activity of heat inactivated sera from immunized
animals was evaluated using a panel of pseudoviruses including
two Clade B (QH0692 and AC10), one Clade C (ZM214) and one
laboratory strain (SF162) (obtained through the NIBSC, Program
EVA Centre for AIDS Reagents, UK), in a standardized and
validated single round infection assay. Stocks of single-round
infection HIV-1 Env pseudoviruses were produced by cotransfect-
ing 293 T/17 cells with 2 mg of an HIV-1 rev/env expression
plasmid and 12 mg of an env-deﬁcient HIV-1 backbone plasmid
(pSG3DEnv) using Lipofectamine transfection reagent (Invitro-
gen). Pseudovirus-containing supernatant was harvested 24 h
following transfection, clariﬁed by centrifugation and ﬁltered
through 0.45 mm ﬁlters, and single-use 1 mL aliquots were stored
at 80 1C. The 50% tissue culture infectious dose (TCID50) for each
pseudovirus preparation was determined by infection of TZM.bl
cells as previously described (Tudor et al., 2009).
TZM.bl neutralization assay
CCR5- and CD4-transfected TZM.bl cell line (JC53-bl obtained
through the NIH AIDS Research and Reference Reagent Program,
USA) was used as target cell for HIV-1 neutralization assay, as
previously described (Tudor et al., 2009). Brieﬂy, 3-fold serial
dilutions of serum samples (starting from 1:10 dilution), were
plated in duplicate (96-well ﬂat bottom plate) in 10% D-MEM
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were added to each well in a volume of 50 mL and incubated for
1 h at 37 1C. TZM.bl cells were then added (1104/well in a
100 ml volume) in 10% D-MEM growth medium containing DEAE-
dextran (Sigma) at a ﬁnal concentration of 11 mg/ml. Assay
controls included replicate wells of TZM.bl cells alone (cell
control) and TZM.bl cells with virus (virus control). Following a
48 h incubation at 37 1C, 150 ml of culture medium were removed
from each well and replaced with 100 ml of Bright-Glo luciferase
reagent (Promega). After a 2 min incubation, 150 ml of the cell
lysate was transferred to a 96-well black solid plate and lumines-
cence was measured using a Victor Light 2030 luminometer
(Perkin Elmer). The 50% inhibitory dose (IC50) was calculated as
the serum dilution that induced a 50% reduction in relative
luminescence units (RLU) compared to the virus control wells,
after subtraction of cell control RLU. A pool of 2F5, b12 and 2G12
neutralizing monoclonal antibodies (TRIMAB) was used at 7.4,
2.5, 0.82 and 0.27 mg/ml, as positive control. A pool of 3 pre-
immune mice antisera was used as negative control. Results are
shown as % of infectivity reduction per each serum after sub-
tracting values observed with pool of pre-immune sera.Antibody Dependent Cellular Cytotoxicity assay (ADCC activity)
ADCC tests were performed using CEM-NKr coated with each
gp41 peptide as indicated for target cells. Brieﬂy, NKr-CEM
expressing CCR5 and THP1, were obtained from the AIDS
Research and Reference Reagent Program, NIH. ADCC was per-
formed using a rapid ﬂuorescent-based assay as recently
described (Tudor and Bomsel, 2011).
Target cells at 3106 cells/mL were coated with 5 mM of each
peptide, as indicated for 1 h at RT and dually stained with the
cytosolic dye CFSE: 5-(and -6-)-carboxyﬂuorescein diacetate succi-
nimidyl ester (Molecular Probes, Eugene, OR, USA) at 1 mM and the
membrane dye PKH-26 (Sigma, St. Louis, MO, USA) at 1 mM for
5 min at 37 1C. After staining, target cells were incubated with the
antibodies (serum samples at the indicated dilution, or 2F5 IgG as
positive control or with irrelevant IgG as negative control) for
30 min at room temperature. Effector cells, THP1, were then added
at an Effector:Target (E:T) ratio of 10:1. Then, cell co-cultures were
incubated for 4 h at 37 1C. Fluorescence proﬁles of the cell co-
cultures were immediately acquired using a Becton Dickinson
FACSCalibur. Data analysis was performed using Cytomics RXP
software. Flow cytometry dot plot of dual-stained target cells
incubated in the same conditions as the effector–target co-cultures,
is used to set the gate of living double positive target cells, in which
the cell membrane is still intact. ADCC is calculated as follows:
(% of PKH-26 highCFSE negative cells)/(% of PKH-26 highCFSE
negative cells)þ(% of PKH-26highCFSEhighcells)100.
When HIV-infected cells were used as target, the ADCC was
corrected by the actual amount of HIV-1 infected cells present at
the beginning of the assay, as determined by intra-cellular p24
labeling (as indicated above). Percent of ADCC lysis is estimated
as the difference in amount killing in presence and absence of a
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